EpiCept Corporation (NASDAQ: EPCT)

EpiCept Corporation (NASDAQ: EPCT), a specialty pharmaceutical company, is focused on meeting unmet medical needs in cancer treatment and pain management. The company has approval from the European Commission to use Ceplene for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Additionally, EpiCept is utilizing its biopharmaceutical discovery capabilities for the discovery and advancement of apoptosis inducers. For further information, visit the Company’s web site at www.epicept.com.